Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?Fda livtencity approval letter march 23 2021 regulatory project managerWhen does the patent expire on ibranceAdefovir dipivoxil discount card
See the DrugPatentWatch profile for Nusinersen
Nusinersen (Spinraza) received its European Medicines Agency (EMA) orphan designation on 20 June 2012. [1]
EMA orphan designation is granted for medicines intended to treat, prevent, or diagnose rare diseases in the EU. The designation date is the date EMA records the medicine as eligible for orphan status, separate from the later date of marketing authorization. [1]
You can confirm the date in EMA’s product/orphan designation information using the Spinraza (nusinersen) entry shown in the source record. [1] Sources: [1] https://www.ema.europa.eu/en/medicines/orphan-designations/eu-orphan-designations-database/nusinersen
Other Questions About Nusinersen :